Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece

Nikos Maniadakis (), Mattias Ekman (), Vasilios Fragoulakis, Vasiliki Papagiannopoulou () and John Yfantopoulos ()

The European Journal of Health Economics, 2011, vol. 12, issue 3, pages 253-261

Keywords: Hypertension; Angiotensin-II inhibitors; Irbesartan; Economic; Cost; Effectiveness; D61; I19; C44; C02 (search for similar items in EconPapers)
Date: 2011
References: View references in EconPapers View complete reference list from CitEc
Citations Track citations by RSS feed

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-010-0243-5 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:spr:eujhec:v:12:y:2011:i:3:p:253-261

Ordering information: This journal article can be ordered from
http://link.springer.de/orders.htm

The European Journal of Health Economics is edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer
Series data maintained by Guenther Eichhorn ().